<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Pinkeova A</submitter><funding>Agentúra na Podporu Výskumu a Vývoja</funding><funding>BBMRI-CZ: Biobank network</funding><funding>HORIZON EUROPE European Innovation Council</funding><pagination>e0300430</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10947713</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>19(3)</volume><pubmed_abstract>The glycoprofiling of two proteins, the free form of the prostate-specific antigen (fPSA) and zinc-α-2-glycoprotein (ZA2G), was assessed to determine their suitability as prostate cancer (PCa) biomarkers. The glycoprofiling of proteins was performed by analysing changes in the glycan composition on fPSA and ZA2G using lectins (proteins that recognise glycans, i.e. complex carbohydrates). The specific glycoprofiling of the proteins was performed using magnetic beads (MBs) modified with horseradish peroxidase (HRP) and antibodies that selectively enriched fPSA or ZA2G from human serum samples. Subsequently, the antibody-captured glycoproteins were incubated on lectin-coated ELISA plates. In addition, a novel glycoprotein standard (GPS) was used to normalise the assay. The glycoprofiling of f</pubmed_abstract><journal>PloS one</journal><pubmed_title>Glycoprofiling of proteins as prostate cancer biomarkers: A multinational population study.</pubmed_title><pmcid>PMC10947713</pmcid><funding_grant_id>APVV-21-0329 and APVV-20-0476</funding_grant_id><funding_grant_id>CZ.02.1.01/0.0/0.0/16_013/000167 and LM2015089</funding_grant_id><funding_grant_id>190185443</funding_grant_id><pubmed_authors>Jirasko M</pubmed_authors><pubmed_authors>Horninger W</pubmed_authors><pubmed_authors>Pinkeova A</pubmed_authors><pubmed_authors>Jane E</pubmed_authors><pubmed_authors>Dubjakova P</pubmed_authors><pubmed_authors>Eder IE</pubmed_authors><pubmed_authors>Kucera R</pubmed_authors><pubmed_authors>Bartova R</pubmed_authors><pubmed_authors>Klocker H</pubmed_authors><pubmed_authors>Tkac J</pubmed_authors><pubmed_authors>Hroncekova S</pubmed_authors><pubmed_authors>Fillo J</pubmed_authors><pubmed_authors>Bertokova A</pubmed_authors><pubmed_authors>Sievert KD</pubmed_authors><pubmed_authors>Fabinyova E</pubmed_authors><pubmed_authors>Bertok T</pubmed_authors><pubmed_authors>Sokol R</pubmed_authors><pubmed_authors>Tomikova A</pubmed_authors></additional><is_claimable>false</is_claimable><name>Glycoprofiling of proteins as prostate cancer biomarkers: A multinational population study.</name><description>The glycoprofiling of two proteins, the free form of the prostate-specific antigen (fPSA) and zinc-α-2-glycoprotein (ZA2G), was assessed to determine their suitability as prostate cancer (PCa) biomarkers. The glycoprofiling of proteins was performed by analysing changes in the glycan composition on fPSA and ZA2G using lectins (proteins that recognise glycans, i.e. complex carbohydrates). The specific glycoprofiling of the proteins was performed using magnetic beads (MBs) modified with horseradish peroxidase (HRP) and antibodies that selectively enriched fPSA or ZA2G from human serum samples. Subsequently, the antibody-captured glycoproteins were incubated on lectin-coated ELISA plates. In addition, a novel glycoprotein standard (GPS) was used to normalise the assay. The glycoprofiling of f</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024</publication><modification>2026-07-15T02:32:54.471Z</modification><creation>2025-05-31T23:16:54.471Z</creation></dates><accession>S-EPMC10947713</accession><cross_references><pubmed>38498504</pubmed><doi>10.1371/journal.pone.0300430</doi></cross_references></HashMap>